

Hong C Shen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4060750/publications.pdf>

Version: 2024-02-01

84
papers

3,250
citations

136950

32
h-index

168389

53
g-index

85
all docs

85
docs citations

85
times ranked

3823
citing authors

#	ARTICLE	IF	CITATIONS
1	Intramolecular Nâ€“Me and Nâ€“H aminoetherification for the synthesis of <i>N</i> -unprotected 3-amino-O-heterocycles. <i>Organic and Biomolecular Chemistry</i> , 2021, 19, 557-560.	2.8	8
2	Efficient synthesis of perfluoroalkylated quinolines via a metal-free cascade Michael addition/intramolecular rearrangement cyclization process. <i>Tetrahedron</i> , 2020, 76, 131518.	1.9	10
3	Discovery of Pyrido[2,3- <i>b</i>]indole Derivatives with Gram-Negative Activity Targeting Both DNA Gyrase and Topoisomerase IV. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 9623-9649.	6.4	38
4	Discovery of 3-Pyridyl Isoindolin-1-one Derivatives as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 6876-6897.	6.4	14
5	Synthesis of NHâ€“Sulfoximines by Using Recyclable Hypervalent Iodine(III) Reagents under Aqueous Micellar Conditions. <i>ChemSusChem</i> , 2020, 13, 922-928.	6.8	22
6	Which cancer type has the highest risk of COVID-19 infection?. <i>Journal of Infection</i> , 2020, 81, 647-679.	3.3	80
7	Fluorofenidone affects hepatic stellate cell activation in hepatic fibrosis by targeting the TGFâ€“1/Smad and MAPK signaling pathways. <i>Experimental and Therapeutic Medicine</i> , 2019, 18, 41-48.	1.8	11
8	A New Approach of Mitigating CYP3A4 Induction Led to the Discovery of Potent Hepatitis B Virus (HBV) Capsid Inhibitor with Optimal ADMET Profiles. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 10352-10361.	6.4	6
9	<i>De novo</i> synthesis, structural assignment and biological evaluation of pseudopaline, a metallophore produced by <i>Pseudomonas aeruginosa</i> . <i>Chemical Science</i> , 2019, 10, 6635-6641.	7.4	22
10	Discovery of Ziresovir as a Potent, Selective, and Orally Bioavailable Respiratory Syncytial Virus Fusion Protein Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 6003-6014.	6.4	39
11	Discovery of (aza)indole derivatives as novel respiratory syncytial virus fusion inhibitors. <i>MedChemComm</i> , 2019, 10, 970-973.	3.4	1
12	Facile synthesis of fluoroalkylated quinolones using fluoroalk-2-ynoates as fluorinated building blocks. <i>Journal of Fluorine Chemistry</i> , 2019, 220, 54-60.	1.7	9
13	Efficient cyclopropanation of aryl/heteroaryl acetates and acetonitriles with vinyl diphenyl sulfonium triflate. <i>Tetrahedron Letters</i> , 2018, 59, 1443-1445.	1.4	5
14	Discovery of Small Molecule Therapeutics for Treatment of Chronic HBV Infection. <i>ACS Infectious Diseases</i> , 2018, 4, 257-277.	3.8	44
15	Palladium-Catalyzed Difluoromethylation of Aryl Chlorides and Triflates and Its Applications in the Preparation of Difluoromethylated Derivatives of Drug/Agrochemical Molecules. <i>Journal of Organic Chemistry</i> , 2018, 83, 1077-1083.	3.2	35
16	Efficient Synthesis of Fluoroalkylated Imidazoles via a Metalâ€“Free Cascade Michael Addition/Azidation/Cycloamination Process. <i>European Journal of Organic Chemistry</i> , 2018, 2018, 6758-6763.	2.4	12
17	Discovery of RG7834: The First-in-Class Selective and Orally Available Small Molecule Hepatitis B Virus Expression Inhibitor with Novel Mechanism of Action. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 10619-10634.	6.4	49
18	Discovery of Benzoazepinequinoline (BAQ) Derivatives as Novel, Potent, Orally Bioavailable Respiratory Syncytial Virus Fusion Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 10228-10241.	6.4	27

#	ARTICLE	IF	CITATIONS
19	Highly Chemo- and Regioselective Vinylation of <i>N</i> -Heteroarenes with Vinylsulfonium Salts. <i>Journal of Organic Chemistry</i> , 2018, 83, 8627-8635.	3.2	19
20	Potassium Iodide-Promoted One-Pot Synthesis of Fluoroalkylated Quinoxalines via a Tandem Michael Addition/Azidation/Cycloamination Approach. <i>Journal of Organic Chemistry</i> , 2018, 83, 9422-9429.	3.2	12
21	Zinc triflate-mediated cyclopropanation of oxindoles with vinyl diphenyl sulfonium triflate: a mild reaction with broad functional group compatibility. <i>RSC Advances</i> , 2017, 7, 3741-3745.	3.6	31
22	Heteroaryldihydropyrimidine (HAP) and Sulfamoylbenzamide (SBA) Inhibit Hepatitis B Virus Replication by Different Molecular Mechanisms. <i>Scientific Reports</i> , 2017, 7, 42374.	3.3	103
23	Synthesis of Bridged Bicyclic Morpholine Amino Acids as Compact Modules for Medicinal Chemistry. <i>Chemistry Letters</i> , 2017, 46, 566-568.	1.3	3
24	Discovery and Pre-Clinical Characterization of Third-Generation 4-H Heteroaryldihydropyrimidine (HAP) Analogues as Hepatitis B Virus (HBV) Capsid Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 3352-3371.	6.4	46
25	Eaton's reagent-mediated metal-free and efficient synthesis of NH-sulfoximines. <i>Tetrahedron Letters</i> , 2017, 58, 333-337.	1.4	11
26	Discovery of methylsulfonyl indazoles as potent and orally active respiratory syncytial Virus (RSV) fusion inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2017, 138, 1147-1157.	5.5	16
27	C-H Bond Functionalization of Tetrahydropyridopyrimidines and Other Related Heterocycles. <i>Journal of Organic Chemistry</i> , 2017, 82, 13678-13685.	3.2	7
28	Efficient synthesis of functionalized chromones via a two-base mediated formal [3+3] cycloaddition. <i>Tetrahedron Letters</i> , 2016, 57, 2116-2120.	1.4	10
29	Discovery of Piperazinylquinoline Derivatives as Novel Respiratory Syncytial Virus Fusion Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 558-562.	2.8	29
30	Design and Synthesis of Orally Bioavailable 4-Methyl Heteroaryldihydropyrimidine Based Hepatitis B Virus (HBV) Capsid Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 7651-7666.	6.4	59
31	Discovery of Fluoromethylketone-Based Peptidomimetics as Covalent ATG4B (Autophagin-1) Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 802-806.	2.8	54
32	Habitat-specific differences in adaptation to light in freshwater diatoms. <i>Journal of Applied Phycology</i> , 2016, 28, 227-239.	2.8	11
33	Alternative tandem cyclisation pathways in the reaction between imines and enones. <i>Tetrahedron</i> , 2016, 72, 1105-1113.	1.9	3
34	Synthesis of novel and conformationally constrained bridged amino acids as compact modules for drug discovery. <i>Tetrahedron Letters</i> , 2016, 57, 599-602.	1.4	6
35	Discovery of Benzimidazole Oxazolinediones as Novel and Selective Nonsteroidal Mineralocorticoid Receptor Antagonists. <i>ACS Medicinal Chemistry Letters</i> , 2015, 6, 461-465.	2.8	14
36	Discovery of Imidazopyridine Derivatives as Highly Potent Respiratory Syncytial Virus Fusion Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2015, 6, 359-362.	2.8	73

#	ARTICLE	IF	CITATIONS
37	Asymmetric Synthesis and Application of Homologous Pyrroline-2-alkylboronic Acids: Identification of the B-N Distance for Eliciting Bifunctional Catalysis of an Asymmetric Aldol Reaction.. Asian Journal of Organic Chemistry, 2014, 3, 470-479.	2.7	11
38	Structure-Based Design and Synthesis of Potent Cyclic Peptides Inhibiting the YAP-TEAD Protein-Protein Interaction. ACS Medicinal Chemistry Letters, 2014, 5, 993-998.	2.8	130
39	Dissolved organic carbon and relationship with bacterioplankton community composition in 3 lake regions of Lake Taihu, China. Canadian Journal of Microbiology, 2014, 60, 669-680.	1.7	11
40	Mineralocorticoid receptor antagonists: Identification of heterocyclic amide replacements in the oxazolidinedione series. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 1681-1684.	2.2	23
41	Discovery of novel oxazolidinedione derivatives as potent and selective mineralocorticoid receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 4388-4392.	2.2	14
42	Novel Therapeutics in Discovery and Development for Treatment of Chronic HBV Infection. Annual Reports in Medicinal Chemistry, 2013, 48, 265-281.	0.9	7
43	Gold-catalyzed formation of heterocycles - an enabling new technology for medicinal chemistry. Drug Discovery Today: Technologies, 2013, 10, e3-e14.	4.0	22
44	One-pot synthesis of useful heterocycles in medicinal chemistry using a cascade strategy. Green Chemistry, 2012, 14, 580.	9.0	27
45	Discovery of Inhibitors of Soluble Epoxide Hydrolase: A Target with Multiple Potential Therapeutic Indications. Journal of Medicinal Chemistry, 2012, 55, 1789-1808.	6.4	199
46	The discovery of non-benzimidazole and brain-penetrant prolylcarboxypeptidase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 658-665.	2.2	15
47	Discovery of benzodihydroisofurans as novel, potent, bioavailable and brain-penetrant prolylcarboxypeptidase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 1550-1556.	2.2	7
48	Discovery of benzimidazole pyrrolidinyl amides as prolylcarboxypeptidase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 1299-1305.	2.2	19
49	Discovery of a Biaryl Cyclohexene Carboxylic Acid (MK-6892): A Potent and Selective High Affinity Niacin Receptor Full Agonist with Reduced Flushing Profiles in Animals as a Preclinical Candidate. Journal of Medicinal Chemistry, 2010, 53, 2666-2670.	6.4	45
50	Discovery of pyrazolyl propionyl cyclohexenamide derivatives as full agonists for the high affinity niacin receptor GPR109A. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 3372-3375.	2.2	11
51	High-Affinity Niacin Receptor GPR109A Agonists. Annual Reports in Medicinal Chemistry, 2010, 45, 72-94.	0.9	14
52	Soluble epoxide hydrolase inhibitors: a patent review. Expert Opinion on Therapeutic Patents, 2010, 20, 941-956.	5.0	71
53	The morphometrical analysis on the ultrastructure of A549 cells. Romanian Journal of Morphology and Embryology, 2010, 51, 663-7.	0.8	32
54	Acyl hydroxypyrazoles as novel agonists for high-affinity nicotinic acid receptor GPR109A: WO2008051403. Expert Opinion on Therapeutic Patents, 2009, 19, 1149-1155.	5.0	7

#	ARTICLE	IF	CITATIONS
55	Expression of thyroid transcription factor-1 (TTF-1) in lung carcinomas and its correlations with apoptosis and angiogenesis. <i>Chinese Journal of Clinical Oncology</i> , 2009, 6, 16-20.	0.0	1
56	Synthesis and biological evaluation of platensimycin analogs. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 1623-1627.	2.2	53
57	Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 3398-3404.	2.2	41
58	Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 5314-5320.	2.2	24
59	A strategy of employing aminoheterocycles as amide mimics to identify novel, potent and bioavailable soluble epoxide hydrolase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 5716-5721.	2.2	32
60	Palladium-Catalyzed Suzuki-Miyaura Coupling of Pyridyl-2-boronic Esters with Aryl Halides Using Highly Active and Air-Stable Phosphine Chloride and Oxide Ligands. <i>Organic Letters</i> , 2009, 11, 381-384.	4.6	119
61	Novel patent publications on high-affinity nicotinic acid receptor agonists. <i>Expert Opinion on Therapeutic Patents</i> , 2009, 19, 957-967.	5.0	25
62	Discovery of a Highly Potent, Selective, and Bioavailable Soluble Epoxide Hydrolase Inhibitor with Excellent Ex Vivo Target Engagement. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 5009-5012.	6.4	42
63	Discovery of Novel Tricyclic Full Agonists for the G-Protein-Coupled Niacin Receptor 109A with Minimized Flushing in Rats. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 2587-2602.	6.4	62
64	Tetrahydro anthranilic acid as a surrogate for anthranilic acid: Application to the discovery of potent niacin receptor agonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 3163-3167.	2.2	29
65	Discovery of pyrazolopyrimidines as the first class of allosteric agonists for the high affinity nicotinic acid receptor GPR109A. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 4948-4951.	2.2	20
66	Discovery of Biaryl Anthranilides as Full Agonists for the High Affinity Niacin Receptor. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 6303-6306.	6.4	35
67	Gold(I)-Catalyzed Regioselective Cyclizations of Silyl Ketene Amides and Carbamates with Alkynes. <i>Journal of Organic Chemistry</i> , 2007, 72, 6287-6289.	3.2	81
68	Discovery of orally bioavailable and novel urea agonists of the high affinity niacin receptor GPR109A. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 6723-6728.	2.2	18
69	$\hat{\pm}$ -Heteroarylation of Esters, Lactones, Amides, and Lactams by Nucleophilic Aromatic Substitution. <i>Organic Letters</i> , 2006, 8, 1447-1450.	4.6	23
70	Syntheses of Seven-Membered Rings: Ruthenium-Catalyzed Intramolecular [5+2] Cycloadditions. <i>Chemistry - A European Journal</i> , 2005, 11, 2577-2590.	3.3	126
71	Biomimetic Enantioselective Total Synthesis of ($\hat{\pm}$)-Siccanin via the Pd-Catalyzed Asymmetric Allylic Alkylation (AAA) and Sequential Radical Cyclizations. <i>Journal of the American Chemical Society</i> , 2004, 126, 12565-12579.	13.7	99
72	Synthesis of Chiral Chromans by the Pd-Catalyzed Asymmetric Allylic Alkylation (AAA): $\hat{\pm}$ Scope, Mechanism, and Applications. <i>Journal of the American Chemical Society</i> , 2004, 126, 11966-11983.	13.7	169

#	ARTICLE	IF	CITATIONS
73	Gene expression and mucosal immune responses after vaginal DNA immunization in mice using a controlled delivery matrix. <i>Journal of Controlled Release</i> , 2003, 86, 339-348.	9.9	48
74	A Formal [3 + 3] Cycloaddition Reaction. Improved Reactivity Using \hat{I}^{\pm}, \hat{I}^2 -Unsaturated Iminium Salts and Evidence for Reversibility of \hat{I}^{\pm} -Electron Electrocyclic Ring Closure of 1-Oxatrienes. <i>Journal of Organic Chemistry</i> , 2003, 68, 1729-1735.	3.2	77
75	On the Diastereoselectivity of Ru-Catalyzed [5 + 2] Cycloadditions. <i>Organic Letters</i> , 2003, 5, 4149-4151.	4.6	48
76	Unusual Effects in the Pd-Catalyzed Asymmetric Allylic Alkylations: A Synthesis of Chiral Chromans. <i>Journal of the American Chemical Society</i> , 2003, 125, 9276-9277.	13.7	122
77	A Synthesis of Trisubstituted Alkenes by a Ru-Catalyzed Addition. <i>Chemistry - A European Journal</i> , 2002, 8, 2341.	3.3	40
78	Stereoselective trans- and cis-Dihydroxylations of 2H-Pyranyl and Dihydropyridinyl Heterocycles Synthesized from Formal [3 + 3]-Cycloaddition Reactions of \hat{I}^{\pm}, \hat{I}^2 -Unsaturated Iminium Ions with 1,3-Dicarbonyl Equivalents. <i>Organic Letters</i> , 2001, 3, 2141-2144.	4.6	32
79	Chiral cycloalkylidene \hat{I}^{\pm}, \hat{I}^2 -unsaturated iminium approach to stereoselective formal [3+3] cycloaddition reaction in spiroheterocycle synthesis. <i>Tetrahedron Letters</i> , 2001, 42, 609-613.	1.4	27
80	Constructing Tricyclic Compounds Containing a Seven-Membered Ring by Ruthenium-Catalyzed Intramolecular. <i>Angewandte Chemie - International Edition</i> , 2001, 40, 2313-2316.	13.8	8
81	On the Regioselectivity of the Ru-Catalyzed Intramolecular [5 + 2] Cycloaddition. <i>Organic Letters</i> , 2000, 2, 2523-2525.	4.6	78
82	Synthesis and UV Studies of A Small Library of 6-Aryl-4-hydroxy-2-pyrones. A Relevant Structural Feature for the Inhibitory Property of Arisugacin Against Acetylcholinesterase. <i>Tetrahedron</i> , 1999, 55, 13683-13696.	1.9	57
83	Synthesis of dihydroxanthone derivatives and evaluation of their inhibitory activity against acetylcholinesterase: Unique structural analogs of tacrine based on the BCD-ring of arisugacin. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1999, 9, 973-978.	2.2	21
84	Sequential 1,2-Addition and Electrocyclic Ring Closures Involving Acyclic \hat{I}^{\pm}, \hat{I}^2 -Unsaturated Iminiums: A Formal [3 + 3] Cycloaddition Strategy to Unique Pyranyl Spirocycles. <i>Journal of Organic Chemistry</i> , 1999, 64, 690-691.	3.2	89